# Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL

> **NCT07120633** · NA · RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 50 (estimated)

## Conditions studied

- CLL
- CAR-T Cell Therapy
- SLL

## Interventions

- **OTHER:** AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients

## Key facts

- **NCT ID:** NCT07120633
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07120633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07120633, "Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07120633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*